Related Experiment Video

Updated: Jun 3, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

453

Clinical advances of mRNA vaccines for cancer immunotherapy

Alexey V Yaremenko1, Muhammad Muzamil Khan1, Xueyan Zhen1

  • 1Center for Nanomedicine, Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Med (New York, N.Y.)
|January 11, 2025
PubMed

Insights

Messenger RNA (mRNA) cancer vaccines show promise across many cancer types by activating the immune system. Ongoing research focuses on improving delivery and immune response for better patient outcomes in oncology.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Messenger RNA (mRNA) vaccines represent a significant advancement in cancer therapy.
  • Over 120 clinical trials are investigating mRNA vaccines for various cancers, including lung, breast, prostate, melanoma, pancreatic, and brain tumors.

Purpose of the Study:

  • To provide a comprehensive overview of recent clinical progress in mRNA cancer vaccines.
  • To discuss innovative strategies for overcoming challenges in delivery and immune response regulation.
  • To explore future directions, including CRISPR-Cas9 integration and advanced mRNA design.

Main Methods:

  • Review of current clinical trials and research in mRNA cancer vaccines.
  • Analysis of mechanisms of action, including tumor-specific antigens and immune stimulation.
  • Exploration of novel delivery systems and immune response modulation techniques.

Main Results:

  • Demonstrated potential of mRNA vaccines across a wide range of malignancies.
  • Identification of key challenges in efficient delivery and precise immune response control.
  • Highlighting of ongoing research and clinical trial advancements.

Conclusions:

  • mRNA cancer vaccines hold transformative potential for advancing oncology.
  • Continued innovation in delivery, immune regulation, and mRNA design is crucial.
  • Further research and clinical trials are essential to improve patient outcomes.
Keywords:
◼◼◼

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.3K

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
336
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
469
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K